"We are encouraged by [this] data, which support[s] the potential benefit of booster doses across all examined age groups," commented Juan Carlos Jaramillo, Valneva's chief medical officer.

the paediatric population is at the greatest risk of Lyme disease," pointed out Juan Carlos Jaramillo, Valneva's chief medical officer. "These first paediatric results are therefore extremely ...

and strengthening the possibilities of inducing a long-lasting antibody response with our chikungunya vaccine candidate,” commented Valneva’s chief medical officer, Juan Carlos Jaramillo.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative ...

Data has since shown this response can be maintained for at least three years in both younger and older adults, Valneva said. The company’s chief medical officer, Juan Carlos Jaramillo, said: “With ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, “This latest approval is a further recognition of IXCHIQ®’s strong product profile and the medical need for a ...

Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, "Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older The European Commission (EC) will now review ...